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Background: The association of long term combined hormone based contraceptives (CHC) use on bone mineral
content (BMC) and areal bone mineral density (aBMD) development remains controversial, as it appears that
the relationship may be age-dependent. The purpose of this study was to investigate the long-term associations
of CHC exposure on the accrual of bone parameters from adolescence into young-adulthood.
Methods: 110women (67 exposed to CHC)were drawn from the Pediatric BoneMineral Accrual Study (PBMAS).
Serial measures of total body (TB), lumbar spine (LS) and femoral neck (FN) BMC and aBMD were assessed by
DXA (a total of 950 scans) and aligned by biological age (BA, years from peak height velocity [PHV]). Multilevel
random effects models were constructed to assess the time dependent associations between annual CHC expo-
sure and the development of bone parameters.
Results: After BA, height, lean tissuemass, fat mass, calcium and vitamin D intake, and physical activity were con-
trolled, it was observed that those individuals exposed to CHC 6-years post PHV developed signiﬁcantly less (−
0.00986±0.00422 g/cm2) TB aBMD than their non CHC exposed peers. Additionally, therewere signiﬁcant BA by
CHC exposure interactions, where CHC exposure 6-years or more post PHV resulted in developing less TB BMC
(−4.94 ± 2.41 g), LS BMC (−0.29 ± 0.11 g) and LS aBMD (−0.00307 ± 0.00109 g/cm2). One year after the at-
tainment of PHV, CHC users were predicted to have 1.2% more TB BMC, 3.8% more LS BMC and 1.7% more LS
aBMD than non-users. At 9-years post PHV the predicted differences showed that CHC users had 0.9% less TB
BMC and 2.7% less LS BMC and 1.6% less LS BMD than those not exposed to CHC.
Conclusions: CHC may not hinder the development of BMC or aBMD during adolescence; however, exposure
6-years or more after PHV may be detrimental.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteoporosis is a skeletal disease that affects millions of individuals
worldwide and is characterized by low areal bone mineral density
(aBMD) and microarchitecture deterioration, leading to increased
bone fragility. Although osteoporosis is a disease associated with frac-
tures in old age, its antecedents are found in adolescence, with the ac-
crual of adolescent bone mass proposed to inﬂuence fracture risk in
adulthood (Bonjour et al., 2009; Baxter-Jones et al., 2011). Estrogen is
a major regulator of bone growth, inﬂuencing the sexual dimorphism
of the skeleton and the maintenance of bone mineral homeostasis,
which in turn alters both the development of bone strength and the ac-
quisition of peak bonemass (Berger et al., 2010). Estrogens act on bonen, 87 Campus Drive, Saskatoon,
Jones).
. This is an open access article underby regulating bone tissue metabolism, primarily through associations
with the promotion of osteoblastic activity and the suppression of oste-
oclastic resorption (Dempster, 2006; Almeida, 2010; Chen et al., 2009;
Zallone, 2006; Tremollieres, 2013). In women, the effects of estrogen
on the skeleton appear most notably during adolescence and after
menopause. During adolescence there is a surge in estrogen levels asso-
ciated with adolescent growth and sexual development, and during
menopause, estrogen levels rapidly decline, exposing women to a
hypoestrogenic state (Tremollieres, 2013). Thus, the exposure to estro-
gen during these key periods may dramatically inﬂuence a woman's
bone health.
Combined hormonal contraceptives (CHC) are one of themost com-
monly usedmethods of contraception (Black et al., 2009). In addition to
contraception though, 88% of CHC users report taking CHC for non-
contraceptive purposes, such as menstrual regulation, menstrual pain
and treating acne (Jones, 2011) thus, it is not unusual to see CHC use be-
ginning as early as 10 years of age and continuing well into adulthood.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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report using CHCs (Black et al., 2009). The associations between CHC
use and bone health remains controversial, with recent evidence sug-
gesting that the association of CHCs may be age dependent
(Tremollieres, 2013; Nappi et al., 2012; Ziglar and Hunter, 2012;
Martins et al., 2006). Prospective observations show that compared
with non-using age similar adolescent or young adult controls, CHC
use is associated with negative changes in areal bone mineral density
(BMD) and content (BMC) (Polatti et al., 1995; Scholes et al., 2010,
2011; Berenson et al., 2008). Other prospective studies show no BMD
differenceswith CHCuse (Bonny et al., 2011; Rome et al., 2004). The ob-
served negative effects during adolescence are thought to be the result
of CHCs reducing the physiological levels of systemic estrodial,
inhibiting the development of peak bone mass (Ziglar and Hunter,
2012; Martins et al., 2006). In adulthood, CHCs appear to provide no
beneﬁt to total body, lumbar spine or femoral neck aBMD in premeno-
pausal women. Associations during the third and fourth decades of life
are unknown. These conﬂicting results from adolescence to adulthood,
highlight the potential age dependent associations that the exposure
to CHCs may have on bone health throughout life; however previous
studies results are often limited to 1 to 3 years in duration, with a limit-
ed number exceeding 5 years of follow-up (Beksinska et al., 2009; Lloyd
et al., 2000), and often fail to control for the duration of CHC use, which
may mediate the relationship between CHCs and bone health (Scholes
et al., 2010, 2011). Additionally, bone undergoes vast changes during
the adolescent period, and has been previously identiﬁed as a critical
window for bonemineral accrual, with nearly 50% of adult bonemineral
mass accrued during the 4 years around peak linear growth (Bailey,
1997; Baxter-Jones et al., 2003, 2010a). Therefore, the initiation of
CHC use may have dramatically different effects on the bone if con-
sumed during this key period of bone development. However, there re-
mains a paucity of longitudinal studies that span the entire adolescent
growth period into adulthood that address whether the exposure to
CHCs is associated with the accrual of bone mass.
The advantage of using longitudinally gathered data is that it is pos-
sible to determine an individual's bone parameter accrual trajectories,
while adjusting for the associations associated with other known con-
founders. The uniqueness of this longitudinal approach to data analysis
is that it accounts for thewide variation shown amongwomen's growth
parameters at any given age, and in the velocity of these parameters
from one age to the next. Growth curves for bone mineral accrual can
be constructed by aligning all subjects on a comparable biological age
index (age from peak height velocity [PHV]) to account for the known
maturational impact on bone growth (Baxter-Jones et al., 2003). The in-
troduction of multilevel statistical models (Goldstein et al., 2002) has
assisted researchers in ﬁtting growth curves to longitudinal measure-
ments over time. In the multilevel framework each individual has
their own straight line growth trajectory, with intercepts and slope co-
efﬁcients varying between individuals. Using this technique the inde-
pendent time dependent effects of growth, maturation, environmental
effects, and CHC usage on BMC and aBMD accrual can be identiﬁed.
Therefore, the purpose of this longitudinal study was to investigate
the time dependent associations of exposure to CHCs on the accrual of
bone mass from adolescence to young adulthood.
2. Methods
2.1. Participants
Women participants were drawn from the University of
Saskatchewan's mixed-longitudinal designed Pediatric Bone Mineral
Accrual Study (PBMAS). The PBMAS has been described in detail else-
where (Bailey et al., 1999; Baxter-Jones et al., 2008). In brief, the
PBMAS cohort consists of 259 individuals (aged 8 to 15 years) recruited
from two elementary schools in the city of Saskatoon between1991 and
1993. The PBMAS began with eight chronological age clusters (8 to15 years) in 1991, with additional recruitment of 8 and 9 year olds in
1992 and 1993. In the initial study phase, data were collected annually
until 1997; after aﬁve-year break data collection resumed andwere col-
lected annually between 2002 and 2011. In 1991 a total of 228 students
(115 girls; 8 to 15 years of age) provided written informed consent to
participate, and 220 children (113 girls) were DXA scanned. By 1997,
197 individuals (aged 12 to 21 years) had been assessed on more than
one occasion (median 6 occasions). From 2003 to 2007 data were col-
lected on 169 returning participants (84 women aged 18 to 31 years)
(median 4 occasions). From 2009 to 2011, 107 participants returned
for another follow-up measurement (65 women aged 23 to 33 years
of age; Table 1). This mixed-longitudinal study design allowed for the
assessment of a 26 year developmental pattern between the ages of
8–33 years, within a 20 year data collection period. At each measure-
ment occasion the same anthropometric, body composition, physical
activity, dietary intakes and bone measures were recorded using the
same instruments. From 2003 onwards CHC usages was recorded as
an additional measure both retrospectively (1991–2001) and prospec-
tively (2002–2011). To be included in the present study participants
were required to be: (i) women; (ii) have a valid assessment of peak
height velocity (PHV); (iii) have at least two DXA assessments (one
during childhood/adolescence and one in young adulthood); (iv) have
a record of CHC use; and (v) have no history of diseases known to affect
growth or bone development. This resulted in the inclusion of 110
young women, with 67 women reporting to have used a CHC at least
once between 1991 and 2011. Table 1 shows the number of women
scanned each year by age group and CHC exposure; note that not all in-
dividualswere assessed at all measurement occasions hence the change
in numbers from year to yearwithin age groups. From 1991 to 2011 the
medium number of scans was 10 (range 1 to 14). A total of 950 scans
were performed over a 20 year period, of these 205 scans were of
women exposed to CHC in the previous 12 months. Written informed
consentwas obtained from all participants (parental assent forminors).
All procedures were approved by the University of Saskatchewan's bio-
medical review committee.
2.2. Anthropometry
Anthropometric measures included height andweight, assessed fol-
lowing the anthropometric standards outlined by Ross and Marfell-
Jones (Ross and Marfell-Jones, 1991). Stretch stature was recorded
without shoes to the nearest 0.1 cm against awall mounted stadiometer
(Holtain Limited, Crymych, UK). Weight was measured on a calibrated
digital scale to the nearest 0.5 kg (Model 1631, Tanita Corp, Tokyo,
Japan).
2.3. Chronological age
A decimal chronologic age (CA, years) was determined by identify-
ing the numbers of days between an individual's date of birth and the
date at the assessment occasion.
2.4. Biological age (peak height velocity) assessments
Biological age (BA, years), a measure of somatic maturation, was de-
ﬁned by identifying the CA of attainment of peak linear growth during ad-
olescence (peak height velocity [PHV]). To determine the CA at PHV,
whole year height velocities were calculated for each participant. A
cubic spline ﬁtting procedure was applied to each individual's whole
year velocity values and the CA at the highest point was estimated
(GraphPad Prism 5, GraphPad Software, San Diego, CA, USA). A BA was
then calculated by subtracting the CA at PHV from the CA at time of
measurement for each individual (e.g. CA at time of measurement =
10.5 years, CA of PHV = 13.4 years, BA at measurement = 10.5 −
13.4 =−2.9 years).
Table 1
Number of women measured in each test year by age group and combined hormone contraceptive (CHC) exposure.
Age 1991 1992 1993 1994 1995 1996 1997 2002 2003 2004 2005 2009–11
8 4 (0) 9 (0) 2 (0)
9 15 (0) 7 (0) 8 (0) 2 (0)
10 10 (0) 16 (0) 8 (0) 10 (0) 2 (0)
11 12 (0) 12 (0) 17 (0) 6 (0) 10 (0) 2 (0)
12 15 (0) 11 (0) 11 (0) 13 (0) 6 (0) 10 (0) 2 (0)
13 16 (0) 16 (0) 11 (0) 11 (0) 13 (0) 6 (0) 7 (0)
14 14 (0) 14 (1) 14 (0) 10 (0) 11 (0) 11 (0) 7 (0)
15 8 (0) 13 (0) 16 (1) 14 (0) 10 (0) 10 (1) 11 (0)
16 8 (0) 13 (1) 9 (1) 10 (3) 5 (1) 6 (1)
17 7 (0) 10 (1) 11 (1) 8 (4) 4 (1) 1 (1)
18 6 (0) 7 (1) 9 (1) 5 (4) 2 (1) 1 (1)
19 5 (0) 6 (0) 5 (2) 6 (4) 1 (1) 1 (1)
20 4 (0) 3 (0) 7 (3) 5 (3) 3 (1)
21 2 (0) 3 (3) 3 (3) 0 (5) 0 (2)
22 3 (6) 3 (4) 6 (3) 3 (4)
23 2 (6) 1 (7) 1 (4) 0 (2)
24 4 (7) 3 (8) 1 (6) 6 (5) 0 (1)
25 4 (1) 5 (5) 5 (8) 2 (6) 1 (0)
26 5 (0) 1 (5) 2 (6) 3 (4) 1 (4)
27 5 (0) 1 (4) 6 (5) 2 (2)
28 3 (0) 5 (6) 3 (2)
29 2 (3) 2 (8)
30 0 (2) 3 (1)
31 0 (9)
32 3 (3)
33 2 (2)
94 (0) 116 (1) 107 (2) 102 (2) 71 (7) 71 (7) 52 (8) 37 (32) 28 (37) 23 (38) 27 (39) 17 (32)
Numbers represent numbers for non-exposed (exposed) to CHC. Note that not all individuals returned for assessment at all measurement occasions hence the change in numbers from
year to year in each age group.
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adolescence and retrospectively in young adulthood.
2.5. Body composition assessments (bone mass, lean tissue mass and fat
mass)
At each measurement occasion participants underwent a dual ener-
gy X-ray absorptiometry (DXA, Hologic QDR-2000/4500, array mode)
scan of the total body (TB), lumbar spine (LS) and proximal femur
(FN) following the procedures outlined in the Hologic operator's manu-
al to assess bonemineral content (BMC, in grams, g), areal bonemineral
density (aBMD, grams per centimeter squared, g/cm2), lean tissuemass
(LTM, kilograms, kg) and fat mass (FM, kilograms, kg). TB BMC, TB
aBMD, LTM and FM were analyzed using software 5.67A. BMC and
aBMD at the lumbar spine and femoral neck were analyzed using soft-
ware version 4.66A. Scanner drift was assessed prior to each scan
using the manufactures lumbar spine phantom and all assessments
were performed by a qualiﬁed licensed technician. The inter-assay pre-
cision (CV%) in vivo for BMC and aBMD measures are 0.60–0.91% and
0.51–0.90%, respectively (Bailey et al., 1996). LTM and FM in our lab
have been also previously reported as CV's of 0.5% and 2.95%, respective-
ly (Bailey et al., 1996, 1999). Between 1991 and2007 scanswere obtain-
ed using the Hologic 2000 scanner, after 2007 scans were obtained
using a Hologic 4500 scanner. To correct for differences between instru-
ments in vivo determined precision across different Hologic instru-
ments was undertaken using results obtained from 9 men and 15
women. From these data we developed conversion factors so that all
outcomes used for analysis represented Hologic 2000 equivalent values
(Baxter-Jones et al., 2010b).
2.6. Dietary assessment
Calcium and vitamin D intakewas assessed annually using a 24 hour
food recall questionnaire. Dietary data were analyzed using the Food
Processor and Nutritional Software (ESHA Research Software, Salem,
OR, USA, Version 8.5). The use of 24-hour food recall has been docu-
mented in this cohort previously and been suggested as an appropriatemethod to assess nutrient intake in children and adults (Whiting and
Shrestha, 1993).2.7. Physical activity assessments
Physical activity (PA) was serially assessed using self-report
questionnaires. Details of the physical activity questionnaires used
have been reported elsewhere (Crocker et al., 1997; Kowalski et al.,
1997, 2004; Copeland et al., 2005). In brief, during childhood and ad-
olescence physical activity was assessed using the Physical Activity
Questionnaire for Children (PAQ-C) and the Physical Activity Ques-
tionnaire for Adolescence (PAQ-A). The PAQ-C/A were designed to
assess general PA levels over the past seven days, scoring nine
items on a ﬁve point Likert-type scale. Final PA scores range from
one to ﬁve, with higher scores indicating higher levels of PA. In adult-
hood, the Physical Activity Questionnaire for Adults (PAQ-AD), a 7
item version of the PAQ-C/A, was used; with individuals' PA scored
on a ﬁve point scale. The PAQ family of questionnaires has been pre-
viously reported to be a valid and reliable measure of PA levels in
children, adolescents and adults (Crocker et al., 1997; Kowalski
et al., 1997; Copeland et al., 2005).2.8. Combined hormonal contraceptive (CHC) measure
Between 2002 and 2011 participants ﬁlled out a lifestyle ques-
tionnaire that assessed contraceptive use. Contraceptive use was
assessed prospectively from 2002 onwards and retrospectively be-
tween 1991 and 2001. The questionnaire consisted of contraceptive
speciﬁc questions such as: Are you currently using oral contracep-
tives? What type of oral contraceptives do you use? How long have
you been using oral contraceptives? What were the age of ﬁrst oral
contraceptive use and the duration of use? The reason for CHC use,
however, was not ascertained at any time point. This questionnaire
was used to categorize each testing occasions as a period of contra-
ceptive use or non-use.
Table 2
General descriptive characteristics of those individuals exposed and not exposed to
combined hormonal contraceptive (CHC) use.
Variable Not exposed to CHC
(n = 43)
Exposed to CHC
(n = 67)
Total
(n = 110)
Age (years) 16.3 ± 5.6 18.0 ± 6.1 a 17.3 ± 5.9
APHV (years) 12.0 ± 1.0 11.8 ± 0.8 11.9 ± 0.9
Age of menarche 12.7 ± 1.1 12.8 ± 1.0 12.7 ± 1.1
Height (cm) 160.0 ± 11.4 162.0 ± 10.6 161.0 ± 11.0
Weight (kg) 58.6 ± 20.5 59.4 ± 18.7 59.0 ± 19.5
LTM (kg) 35.8 ± 8.4 36.7 ± 8.4 36.3 ± 8.4
FM (kg) 31.4 ± 9.9 31.7 ± 8.5 31.6 ± 9.1
Vit D (UI) 217.0 ± 151.0 242.0 ± 173.0 a 231.0 ± 164.0
Calcium (mg) 893.0 ± 395.0 983.0 ± 430.0 a 944.0 ± 415.0
Physical activity 2.6 ± 0.8 2.5 ± 0.7 2.6 ± 0.7
Years of CHC use NA 4.9 ± 3.9 4.9 ± 3.9
APHV= age of peak height velocity; physical activity = physical activity score from sub-
jective questionnaire (score from 1–5).
a Indicates a signiﬁcant difference from the non-users (p b 0.05).
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All variableswere assessed for normality and violationswere adjust-
ed using logarithmic transformations. For the longitudinal analyses,
multilevel (hierarchical) random effects models were constructed
using a multilevel modeling approach (MlwiN version 2.26, Multilevel
Models Project; Institute of Education, University of London, UK (Ross
and Marfell-Jones, 1991)). A detailed description of the multilevel
modeling procedures is presented elsewhere (Baxter-Jones and
Mirwald, 2004). In brief, bone parameters (BMC and aBMD)were mea-
sured repeatedly in individuals (level 1 of the hierarchy) and between
individuals (level 2 of the hierarchy). Analysis models that contain
linked variables measured at different levels of a hierarchy are known
as multilevel random effect regression models. Speciﬁcally, the follow-
ing additive random effects multilevel regression models were adopted
to describe the developmental changes in bone parameters with age.
yi j ¼ α þ μ j
 
þ β þ ν j
 
xi j þ z 1i j þ z 2i j þ…þ z ni j
 þ εi j ð1Þ
which can be reorganized to
yi j ¼ α þ β jxi j
 þ z 1i j þ z 2i j þ…þ z ni j
 þ μ j þ ν jxi j þ εi j
 
: ð2Þ
where: y is the bone parameter (e.g. BMC or aBMD) on measurement
occasion i in the j-th individual; α is a constant; βjxij is the slope of the
bone parameter over time (in the models presented BA is centered
around+5 years fromPHV) for the j-th individual; z_1 to z_n are the co-
efﬁcients of various time dependent explanatory variables (i.e. height,
LTM, FM, calcium intake, vitamin D intake, PA, duration of CHC use,
CHC use (yes = 1 or no = 0) and CHC use by BA interaction) at assess-
ment occasion i in the j-the individual. These are the ﬁxed time depen-
dent parameters in the model.
μ j, vj xij and εij are randomquantities (see Tables 3 to 5),whosemeans
are equal to zero; they form the random parameters in the model. They
are assumed to be uncorrelated and follow a normal distribution and
thus their variances can be estimated; εij ~ N[0,var(εij)] is the level-1 re-
sidual (within individual) variance for the i-th assessment of the bone
parameter in the j-th individual; μ j ~ N[0,var(μ)] is the between individ-
ual intercept variance and vjxij ~ N[0,var(vjxij)] the between individuals
slope variance; these are the level-2 residuals (between subjects) vari-
ances for the j-th individual. μj ∗ vjxij ~ N[0,var(μ j ∗ vjxij)] explains the in-
tercept–slope covariance relationship among the intercepts and slopes in
the model.
Models were built in a stepwise procedure, i.e. predictor variables (z-
ﬁxed effects)were added one at a time, and the log likelihood ratio statis-
tic was used to judge the effects of including further variables on the ﬁt of
the model. BA center (βjxij-centered around + 5 years from PHV) was
added as both a random (level 2) and a ﬁxed variable (Level 1). This per-
mits individuals to have independent intercepts and slopes and a calcula-
tion of the intercept-slope covariance relationship. A signiﬁcant BA
centered coefﬁcients (β) at level 1 of the models indicates that a bone
measure is increasing signiﬁcantly at each measurement occasion within
individuals. Signiﬁcant coefﬁcients at the individuals variance matrix
(level 2) in eachmodel indicates that individuals have signiﬁcantly differ-
ent growth curves for bone measures, both in terms of their intercepts
and the slopes and that the there is a relationship between intercepts
and slopes in the model. Predictor variables (z) were accepted as signiﬁ-
cant if the estimatedmean coefﬁcientwas greater than twice the standard
error of the estimate (SEE, i.e. p b 0.05). If both these retention criteria
were not met the predictor variable was discarded. The power functions
BA centered2 and BA centered3 were introduced into the linear models
to allow for the non-linearity of growth and were retained whether or
not they were signiﬁcant so as to shape the bone developmental curves.
Thepredictor variable coefﬁcients in theﬁnalmodelswereused topredictBMC and aBMDdevelopment at the total body, lumbar spine and femoral
neck with BA, height, LTM, FM, calcium intake, vitamin D intake, PA, CHC
duration of use, CHC use and CHC use by BA centered interaction con-
trolled in the prediction equations using population averages at each BA
category. A total of six independent multilevel (hierarchical) random ef-
fects models were constructed; one for each bone parameter (BMC and
aBMD) at each assessment location (TB, LS and FN).
3. Results
Of the sixty-sevenparticipantswho reportedusing at least one formof
hormone based contraception at a minimum of one time point, 92% of
these individuals reported using a CHC as their method of contraception
(i.e. oral pill), 7% used progestin only methods and 1% using other hor-
mone based forms of contraceptives (i.e. IUD). Results are presented
only for participants who reported use of CHC. All other users were
excluded from the subsequent analyses. Table 2 displays the general char-
acteristics of individuals exposed andnot exposed to CHCusage. Those in-
dividuals exposed to CHC were older, consumed more calcium and
vitamin D than individuals not exposed to CHC use. Only measurement
occasions where CHC use was recorded was an individual considered
being exposed to CHC in the longitudinal analyses. Average age ofmenar-
che was 12.7 years ranging from 9.8 to 15.0 years. The average age at
which participants reported starting CHC use was 19.1 ± 3.4 years
(range 14 to 31 years; Table 1). No individuals in this cohort reported
CHC use prior to menarche.
3.1. Multilevel models and longitudinal analyses
Tables 3–5 summarize the results from the multilevel models for
total body, lumbar spine and femoral neck BMC and aBMDdevelopment
respectively by biological age (BA) centered around+5 years post PHV.
For all models (Tables 3–5), the signiﬁcant BA center random coefﬁ-
cients (β) at level 1 of themodels indicates that bonemeasureswere in-
creasing signiﬁcantly at eachmeasurement occasionwithin individuals.
The between individuals variance matrix (level 2 — μ j and vjxij) for each
model indicates that individuals had signiﬁcantly different growth
curves for bone measures, both in terms of their intercepts (constant
(μ j)), and the slopes of their lines (BA center (vjxij)). The positive BA
centered ∗ constant (μ j ∗ vjxij) coefﬁcient indicates that in the model
there was a relationship between intercepts and slopes, the higher the
intercept the greater the slope.
In the ﬁxed effects it was shown that BA centered, height, LTM, FM
and physical activity signiﬁcantly contributed to the prediction of TB
BMC development (Table 3). Additionally, it was observed that there
was a signiﬁcant CHC user by BA interaction, identifying that those ex-
posed to CHC use had signiﬁcantly less TB BMC (−13.03 ± 6.09 g) for
each year of exposure 6 years or more post PHV attainment (Fig. 1A)
Table 3
Multilevel regressionmodels for total bodybonemineral content (TBBMC) and areal bone
mineral density (TB aBMD).
Variable TB BMC TB aBMD
Fixed effects
Constant −1633.51 ± 209.59 0.74 ± 0.07
BA centered 29.55 ± 2.19 7.86 ± 0.72 a
BA centered2 −1.26 ± 0.34 0.58 ± 0.11a
BA centered3 −0.04 ± 0.02 0.03 ± 0.01 a
Height 14.86 ± 1.38 0.35 ± 0.04 a
LTM 26.48 ± 1.37 a 0.07 ± 0.01 a
FM 6.75 ± 0.82 −1.03 ± 0.27 a
Calcium NS NS
Vitamin D NS NS
PA −13.03 ± 6.09 −7.74 ± 1.91 a
CHC duration of use NS NS
CHC usage NS −9.86 ± 4.22 a
CHC usage ∗ BA −4.94 ± 2.41 NS
Random effects
Level 1
Constant (εij) 6422.33 ± 333.56 0.61 ± 0.03a
Level 2
Constant (μj) 22.78 ± 3.26b 2.48 ± 0.35 a
BA centered (νjXij) 72.1 ± 14.7a 0.01 ± 0.002a
Constant ∗ BA centered (μj ∗ νjXij) 672.9 ± 175.8a 0.05 ± 0.01a
Fixed effect values are estimated mean coefﬁcients ± SEE (standard error estimate) of
BMC (g) and aBMD (g/cm2).
Random effects values estimated mean variance ± SEE [BMC (g) and aBMD (g/cm2)]2.
BA (biological age) centered is BA in years centered on 5 years post peak height velocity
(PHV, years).
Height (cm); total body leanmass (LTM) (g); total body fatmass (FM) (kg); calcium (mg);
vitaminD (UI); PA (physical activity— score from 1–5); CHC usage (CHC use=1, non-use
= 0).
Numerical values are all signiﬁcant, p b 0.05 (mean N 2 ∗ SEE). Non-signiﬁcant variables
are indicated as ‘NS’ and removed from the ﬁnal model.
a Indicates that numerical values are multiplied by 10−3
b Indicates that numerical values are multiplied by 103.
Table 4
Multilevel regression models for lumbar spine bone mineral content (LS BMC) and areal
bone mineral density (LS aBMD).
Variable LS BMC LS aBMD
Fixed effects
Constant −46.38 ± 9.94 NS
BA centered 1.19 ± 0.1 12.73 ± 1.06
BA centered2 −0.07 ± 0.02 −0.70 ± 0.20 a
BA centered3b 0.38 ± 0.09 a NS
Height 0.54 ± 0.04 4.70 ± 0.67
LTM 4.28 ± 0.61 0.06 ± 0.01 a
FM −0.09 ± 0.04 NS
Calcium NS NS
Vitamin D NS NS
PA −0.58 ± 0.28 −5.62 ± 2.76 a
CHC duration of use NS NS
CHC usage NS NS
CHC usage ∗ BA −0.29 ± 0.11 −3.07 ± 1.09 a
Random effects
Level 1
Constant (εij) 11.7 ± 0.65 1.12 ± 0.62 a
Level 2
Constant (μj) 39.74 ± 5.75 6.46 ± 0.91 a
BA centered (νjXij) 0.16 ± 0.03 0.02 ± 0.01 a
Constant ∗ BA centered (μj ∗ νjXij) 0.92 ± 0.33 0.09 ± 0.04 a
Fixed effect values are estimated mean coefﬁcients ± SEE (standard error estimate) of
BMC (g) and aBMD (g/cm2).
Random effects values estimated mean variance ± SEE [BMC (g) and aBMD (g/cm2)]2.
BA (biological age) centered is BA in years centered on 5 years post peak height velocity
(PHV, years).
Height (cm); total body lean mass (LTM) (g); total body fat mass (FM) (kg); calcium
(mg); vitamin D (UI); PA (physical activity — score from 1–5); CHC usage (CHC use =
1, non-use = 0).
Numerical values are all signiﬁcant, p b 0.05 (mean N 2 ∗ SEE). Non-signiﬁcant variables
are indicated as ‘NS’ and removed from the ﬁnal model.
a Indicates that numerical values are multiplied by 10−3.
b Indicates that numerical values are multiplied by 103.
e337S.A. Jackowski et al. / Bone Reports 5 (2016) e333–e341and signiﬁcantly more TB BMC is added up until 5 years post PHV. Sim-
ilarly, BA centered, height, LTM, FM and physical activity signiﬁcantly
contributed to the prediction of TB aBMD development (Table 3), with
those who were exposed to CHC identiﬁed to have signiﬁcantly less
TB aBMD development (−0.00986 ± 0.00422 g/cm2, Fig. 1B). There
was no CHC use by BA centered interaction.
At the lumbar spine, BA centered, height, LTM, FM and PA were sig-
niﬁcant predictors of LS BMC, but only BA centered, height, LTM, and PA
were signiﬁcant predictors of LS aBMD (Table 4); however for both LS
BMC and LS aBMD, there was a signiﬁcant CHC user by BA interaction,
with those exposed to CHC having signiﬁcantly less LSBMC (−0.29 ±
0.11 g) and LS aBMD (−0.00307 ± 0.00109 g/cm2) for each year of ex-
posure 6 years ormore after the attainment of PHV (Fig. 2) and have sig-
niﬁcantly more BMC and BMD in the years prior to +5 years post PHV.
At the femoral neck, it was observed that BA centered, height, LTM
and FM signiﬁcantly predicted the development of FN BMC (Table 5),
while only BA centered, height and LTM signiﬁcantly predicted the de-
velopment of FN aBMD (Table 4). Neither CHC usage nor CHC user by
BA interactions were observed to be signiﬁcant predictors of BMC and
aBMD at the femoral neck (Table 3, Fig. 3).1 Concentrations derived from pharmacokinetic and bioavilability product information
provided by pharmaceutical companies for brands reported by participants.4. Discussion
The aimof this studywas to investigate the long-term associations of
exposure to CHC on the accrual of total body, lumbar spine and femoral
neck bone mass from adolescence to young adulthood. It was observed
that an exposure to CHC 5 years after the attainment of peak height ve-
locity (PHV; ~17–19 years of age) was associated with detrimental de-
velopment of TB BMC, LS BMC and LS aBMD; but that exposure from
PHV to 5 years post PHV was beneﬁcial, in this cohort of healthywomen. Additionally, it was noted that those individuals exposed to
CHCs, throughout adolescence and young adulthood, developed signiﬁ-
cantly lower TB aBMD. This is the ﬁrst study, to our knowledge, to lon-
gitudinally investigate the time dependent associations of exposure to
CHC on the accrual of bone mass measures in healthy young women,
followed from early adolescence into young adulthood.
In teenwomen, peak linear growth occurs, on average, at 12 years of
age, and is landmarked by the milestone PHV. In the 4 years surround-
ing the attainment of PHV, nearly 50% of an individual's BMC is accrued
(Bailey, 1997; Baxter-Jones et al., 2010a) making it a critical period to-
wards adult bone development. Similarly, during adolescence there is
a natural surge in circulating estrogen levels, whichmediates the initia-
tion of puberty and is necessary for linear growth, sexual dimorphismof
the skeleton and epiphyseal closure (Almeida, 2010; Malina et al.,
2004). Given that normal adolescent women have circulating estrogen
concentrations ranging from 40–110 pg/ml and that elevated levels
occur in the morning with the highest concentrations observed follow-
ing the occurrence of menarche (Norjavaara et al., 1996; Albin et al.,
2012), combined hormonal contraceptives that maintain these natural-
ly occurring estrogen levels and follow a consumption schedule similar
to the naturally occurring ebb and ﬂow should provide an environment
favorable to normal, healthy adolescent bone growth and development.
In the present study, of thewomen reporting contraceptive use, 92% re-
ported using CHC pills, consisting of both progestin and ethinyl estradi-
ol, 7% reported using progrestrin only methods (e.g. depoprovera) and,
1% reported using other combined hormonal contraceptive methods
(e.g. IUD). Of the CHC brands reported, they are cited to delivery be-
tween 55–100 pg/ml of ethinyl estradiol1 with normal and regular
Table 5
Multilevel regression models for femoral neck bone mineral content (FN BMC) and areal
bone mineral density (FN aBMD).
Variable FN BMC FN aBMD
Fixed effects
Constant −2.95 ± 0.58 NS
BA centered NS 1.83 ± 0.96 a
BA centered2 −1.88 ± 0.92 a −0.42 ± 0.02 a
BA centered3 NS NS
Height 32.67 ± 3.75 a 2.97 ± 0.59 a
LTM 0.42 ± 0.03 a 0.07 ± 0.01 a
FM 5.81 ± 2.23 a NS
Calcium NS NS
Vitamin D NS NS
PA NS NS
CHC duration of use NS NS
CHC usage NS NS
CHC usage ∗ BA NS NS
Random effects
Level 1
Constant (εij) 52.18 ± 27.12 a 10.00 ± 0.05 a
Level 2
Constant (μj) 0.16 ± 0.02 6.89 ± 0.96 a
BA centered (νjXij) 0.04 ± 0.01 a 0.02 ± 0.003 a
Constant ∗ BA centered (μj ∗ νjXij) 4.52 ± 1.18 a 0.15 ± 0.04 a
Fixed effect values are estimated mean coefﬁcients ± SEE (standard error estimate) of
BMC (g) and aBMD (g/cm2).
Random effects values estimated mean variance ± SEE [BMC (g) and aBMD (g/cm2)]2.
BA (biological age) centered is BA in years centered on 5 years post peak height velocity
(PHV, years).
Height (cm); total body lean mass (LTM) (g); total body fat mass (FM) (kg); calcium
(mg); vitamin D (UI); PA (physical activity score from 1–5); CHC usage (CHC use = 1,
non-use = 0).
Numerical values are all signiﬁcant, p b 0.05 (mean N 2 ∗ SEE). Non-signiﬁcant variables
are indicated as ‘NS’ and removed from the ﬁnal model.
a Indicates that numerical values are multiplied by 10−3.
b Indicates that numerical values are multiplied by 103.
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potency compared to physiological estradiol, these serum levels meet,
and may even exceed, normal circulating levels in healthy pubertal fe-
males. Though there are complex hormonal interactions taking placeFig. 1. Predicted total body bone mineral content (BMC) and areal bone mineral density (aBMD
Predicted models adjusted for BA, height, LTM, FM, calcium intake, vitamin D intake, physical aduring the pubertal period that may further complicate the impact of
CHC use on bone development during this period, it can be reasonably
argued that the CHCs, used by the majority of the current cohort, may
serve to provide a hyperestrogenic environment, conducive to normal
or improved adolescent bone growth and development. The ﬁndings
of the current study support this supposition as it was observed that
there were no signiﬁcant detriments to the development of TB BMC,
LS BMC, LS aBMD, FN BMC and FN aBMD during adolescence in individ-
uals exposed to CHC. In fact there was a positive association with bone
accrual between PHV and 5 years post PHV, with the detrimental effects
not observed to occur until after 5 years post PHV. These observations
support previous literature where combined oral contraceptive use
was investigated during adolescence (Cromer et al., 1996, 2004, 2008)
but dispute other ﬁnding [15.16]. It is important to note that the ﬁnd-
ings of Scholes et al. (Scholes et al., 2010, 2011) may differ from those
presented here because of the different analytical approaches taken.
Whereas the Scholes group reported % change in aBMD, we report
adjusted raw values. Scholes et al. did not control for changes in
maturation between CHC user and controls. As their CHC group was
maturationally older it was possible that what was being observed
was a natural increase in aBMD associated with normal growth. The ad-
vantage of the analytical technique presented in the present study was
that maturational differences were controlled, at all ages suggesting
perhaps the positive effects of CHC use observed after 20 years of age
by the Scholes data could have been due to masking effects related to
maturational differences.
Cromer and colleagues (Cromer et al., 2004) reported that adoles-
centwomen taking CHChad signiﬁcant increases in aBMDat the lumbar
spine and femoral neck after one year of combined oral contraceptive
use, suggesting that signiﬁcant bone growthmay continue to occur dur-
ing adolescence with the regular use of combined oral contraceptives.
However, they also report that controls had signiﬁcantly higher rates
of change to aBMD compared to CHC users. These conﬂicting results
may be a result of differences in oral contraceptive dosage. In the
Cromer et al. study, participants were given a dose of 20 μg/100 μg ethi-
nyl estradiol to progestin while in the current study participants report
brands consisting of formulation of 30 μg/150 μg or higher. The higher
levels associated with these brands may be more conducive to deliver-
ing higher levels of circulating ethinyl estradiol which may be more) between those exposed and not exposed to combined hormonal contraceptives (CHC).
ctivity, duration of use, CHC use at measurement and CHC use by BA interaction.
Fig. 2. Predicted lumbar spine bonemineral content (BMC) and areal bonemineral density (aBMD) between those exposed and not exposed to combined hormonal contraceptives (CHC).
Predicted models adjusted for BA, height, LTM, FM, calcium intake, vitamin D intake, physical activity, duration of use, CHC use at measurement and CHC use by BA interaction.
e339S.A. Jackowski et al. / Bone Reports 5 (2016) e333–e341favorable to adolescent bone development. This conjecture is supported
by Cromer and colleagues' earlier studieswhich employed a higher dos-
age (30 μg/150 μg) and observed that aBMD at the lumbar spine signif-
icantly increased after 1 year, and that these increases were not
signiﬁcantly different between controls and CHC users (Cromer et al.,
1996). It is important to recognize that CHC pill formulations have un-
dergone a reduction in the level of synthetic ethinyl estradiol due to
the documented associations with increased thromboembolic events.
It appears that it is possible that these new lower dose formulations
may reduce the risk of thromboembolisms, butmay also lead to reduced
bone mass accrual if taken during adolescence. Further research isFig. 3. Predicted femoral neck bonemineral content (BMC) and areal bonemineral density (aBM
Predicted models adjusted for BA, height, LTM, FM, calcium intake, vitamin D intake, physical a
difference between groups so lines overlap.required to address the optimal dosage that may beneﬁt future cancer
risk, whilemaintaining optimal bonemass acquisition, given the adoles-
cent reliance on CHC as a method of contraception.
In contrast to the adolescent ﬁndings, exposure to CHC resulted in
lower levels of BMC and aBMD development when consumed 5 years
after PHV is attained, with individuals exposed to CHC having 1–3%
less TB BMC, 2–7% less LS BMC and 2–5% less LS aBMD compared to
those not exposed to CHC. This 5 year PHV period coincides with the
cessation of linear growth and the occurrence of peak bone mass
(Bailey, 1997; Bailey et al., 1999) and may explain these unique age by
exposure interactions. During growth, bone adaptation occurs primarilyD) between those exposed and not exposed to combined hormonal contraceptives (CHC).
ctivity, duration of use, CHC use at measurement and CHC use by BA interaction. Note: no
e340 S.A. Jackowski et al. / Bone Reports 5 (2016) e333–e341through the process of bone modeling, where there is an addition of
bone through the independent actions of osteoblasts and osteoclasts.
Here, elevated ovarian hormone levelsmay reduce osteoclastic bone re-
sorption, but the bone acquisition is not hindered due to the indepen-
dent actions of the osteoblasts. In adulthood, osteoblast and osteoclast
activity are tightly coupled through the process of bone remodeling.
During this period, the elevated ovarian hormone levels may continue
to suppress osteoclastic activity, but because of the coupled process,
there may also be a reduction in osteoblastic proliferation and bone for-
mation. Thus, the exposure to CHC after the cessation of growth may
continue to provide a hyperestrogenic environment, but this is nowhin-
dering bonemass acquisition as a result of a compromised bone remod-
eling process. Additionally, ethinyl estradiol may inﬂuence the binding
afﬁnity of ability of androgen receptors, further limiting bone mass ac-
quisition during this period. These observations contradict previous
studies that largely document no signiﬁcant differences in bone mass
measures in CHCusers during young adulthood. Although discrepancies
in dosage may be attributed to these conﬂicting ﬁndings, there are a
number of studies that report ultra-low dose, low-dose and CHC doses
equivalent to those reported by thepresent cohort to have no signiﬁcant
effect on total body, lumbar spine, femoral neck and heel aBMD (Polatti
et al., 1995; Nappi et al., 2003; Nappi et al., 2005). Alternatively, the con-
ﬂicting results may be due to the duration of use and the follow-up in-
terval. Polatti et al. (Polatti et al., 1995) observed that the aBMD at the
spine was signiﬁcantly different between OC users and controls be-
tween 19–22 years of age after a 5 year follow-up, with non-users
gaining 7.8% more aBMD. In the present study, the duration of use was
not signiﬁcant in the models, but individuals exposed to CHC had re-
ported, on average, 5 years of CHC use (Table 2) and initiated use as
early as 14 years of age (Table 1). This length of exposure is congruent
with Polatti et al. (Polatti et al., 1995), though the earlier age of initiation
may explain the reduced losses (2–5% vs. 7.8%) compared to those
previously reported.
This study provides novel insights into the relationship between
CHC exposure and the development of bone mass, but the conclusions
are limited by a number of factors. First, this study was derived from
observational data and therefore susceptible to uncontrolled variables,
selection bias and reverse causality. The observational nature of this
study is also limited by the assessment and control of CHC type and for-
mulations used. Even though all types of CHC formulations were in-
cluded in this study, all non-oral hormonal contraceptives were
excluded, and most users switched brands and formulations through-
out the duration of the study. Thus, the present study is unable to as-
sess or speculate on any beneﬁts associated with any particular type
of hormone based contraceptive and/or formulation. Similarly, the rea-
son for taking CHC was not identiﬁed and may have inﬂuenced the
bone mineral accrual if CHC usage was prescribed for conditions
known to alter bone mineral accrual (e.g. amenorrhea). Finally, CHC
exposure was determined prospectively for the majority of the cohort,
however, in some participants, initiation of CHC use and exposure was
determined retrospectively, and then followed prospectively. Future
studies should consider usingmedical records to conﬁrm CHC initiation
if assessed by retrospective questionnaires. Despite these limitations,
the present ﬁndings provide novel insight into the development of
BMC and aBMD from adolescence to adulthood for individuals exposed
and not exposed to CHC use.5. Conclusions
In conclusion, there is conﬂicting evidence of the associations be-
tween CHC exposure and bone mass development throughout life.
Although the results of this study are not deﬁnitive, they do suggest
that the exposure to CHC may be detrimental to the development of
BMC and aBMD in females after the cessation of growth has oc-
curred; however, they do not appear to be detrimental to bonemass development during the adolescence period and may even
have a positive effect.
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